Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Sterile-filled to order, with COA and lot documentation
After decades with no disease-modifying drug, 20242026 finally delivered the first targeted therapies: Novartis ianalumab met both NEPTUNUS-1 & NEPTUNUS-2 Phase 3 endpoints and won FDA Breakthrough Therapy status in Jan 2026, and J&Js nipocalimab was positive in the Phase 2 DAHLIAS trial ( The Lancet )
This 15-amino acid peptide activates multiple healing pathways simultaneously
1 The GAG layer prevents toxins, acid, or infectious agents in urine from penetrating the bladder wall
Common areas include the abdomen, thigh, upper arm, and glute area
US$ 26.55
US$ 29.53
US$ 29.76
